BioXcel Therapeutics, Inc. (BTAI)
NASDAQ · Healthcare
BioXcel Therapeutics, Inc. Operating Income 2022–2025
BioXcel Therapeutics, Inc. annual/quarterly operating income history and growth rate from 2022 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- BioXcel Therapeutics, Inc. operating income for the quarter ending March 31, 2026 was -10.2 M, a 1.23% increase year-over-year.
- BioXcel Therapeutics, Inc. operating income for the twelve months ending March 31, 2026 was -50.4 M, a 52.02% decrease year-over-year.
- BioXcel Therapeutics, Inc. annual operating income for 2025 was -50.5 M, a 24.96% decrease from 2024.
- BioXcel Therapeutics, Inc. annual operating income for 2024 was -67.2 M, a 60.85% decrease from 2023.
- BioXcel Therapeutics, Inc. annual operating income for 2023 was -171.8 M, a 7.60% increase from 2022.
- BioXcel Therapeutics, Inc. annual operating income for 2022 was -159.6 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
BioXcel Therapeutics, Inc. Operating Income — FAQ
BioXcel Therapeutics, Inc. (BTAI) operating income over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
What is BioXcel Therapeutics, Inc.'s operating income?
BioXcel Therapeutics, Inc. (BTAI) reported operating income of -$50M for fiscal 2025.
Where can I see BTAI's operating income history?
The chart and table above show BioXcel Therapeutics, Inc.'s operating income by year and by quarter, including the growth rate.